Philip Morris International (PM)
Market Price (7/23/2026): $195.51 | Market Cap: $304.6 BilInvestor Relations Sector: Consumer Staples | Industry: Tobacco
Philip Morris International (PM)
Market Price (7/23/2026): $195.51Market Cap: $304.6 BilSector: Consumer StaplesIndustry: Tobacco
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 6.6%, Dividend Yield is 2.9% Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 37% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 29%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 26%, CFO LTM is 12 Bil, FCF LTM is 11 Bil Low stock price volatilityVol 12M is 29% Megatrend and thematic driversMegatrends include Consumer Lifestyle Transformation. Themes include Tobacco Harm Reduction, Next-Generation Nicotine Products, Smoke-Free Product Innovation, Show more. | Trading close to highsDist 52W High is 0.0%, Dist 3Y High is 0.0% | Expensive valuation multiplesP/SPrice/Sales ratio is 7.3x Key risksPM key risks include [1] targeted regulatory and legal challenges against its core smoke-free products like IQOS and Zyn, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 6.6%, Dividend Yield is 2.9% |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 37% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 29%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 26%, CFO LTM is 12 Bil, FCF LTM is 11 Bil |
| Low stock price volatilityVol 12M is 29% |
| Megatrend and thematic driversMegatrends include Consumer Lifestyle Transformation. Themes include Tobacco Harm Reduction, Next-Generation Nicotine Products, Smoke-Free Product Innovation, Show more. |
| Trading close to highsDist 52W High is 0.0%, Dist 3Y High is 0.0% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 7.3x |
| Key risksPM key risks include [1] targeted regulatory and legal challenges against its core smoke-free products like IQOS and Zyn, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Philip Morris International (PM) stock has gained about 20% since 3/31/2026 because of the following key factors:
1. Philip Morris International reported strong financial performance in both fiscal Q1 2026 and Q2 2026, consistently exceeding analyst expectations for key metrics.
In fiscal Q1 2026, the company's adjusted diluted EPS rose 16.0% to $1.96, surpassing analyst estimates of $1.89. Net revenues also increased 9.1% to $10.1 billion. This momentum continued into fiscal Q2 2026, with adjusted diluted EPS growing 15.2% to $2.20, beating estimates of $2.04 to $2.11. During Q2 2026, net revenues rose 10.4% to $11.2 billion, exceeding estimates of $10.6 billion to $10.96 billion, marking the first time the company's quarterly net revenue surpassed $11 billion. The stock price gained approximately 17.08% from an adjusted price of $165.34 on March 31, 2026, to $193.58 in premarket trading on July 22, 2026, following the Q2 earnings release.
2. The company demonstrated accelerated growth in its smoke-free product portfolio, which continues to be a primary revenue driver.
Philip Morris International's strategic shift towards reduced-risk products, including IQOS, VEEV, and ZYN, fueled significant growth. In fiscal Q1 2026, international smoke-free net revenues surged 24.7% (15.8% organically). This trend strengthened in fiscal Q2 2026, as smoke-free net revenues grew 14.2% (11.8% organically) and represented approximately 42% of total net revenues. Shipments of smoke-free products increased by 7.5% in Q2 2026, contributing to overall volume and market share gains in key international markets.
Show more
Philip Morris International (PM) stock has gained about 20% since 3/31/2026 because of the following key factors:
1. Philip Morris International reported strong financial performance in both fiscal Q1 2026 and Q2 2026, consistently exceeding analyst expectations for key metrics.
In fiscal Q1 2026, the company's adjusted diluted EPS rose 16.0% to $1.96, surpassing analyst estimates of $1.89. Net revenues also increased 9.1% to $10.1 billion. This momentum continued into fiscal Q2 2026, with adjusted diluted EPS growing 15.2% to $2.20, beating estimates of $2.04 to $2.11. During Q2 2026, net revenues rose 10.4% to $11.2 billion, exceeding estimates of $10.6 billion to $10.96 billion, marking the first time the company's quarterly net revenue surpassed $11 billion. The stock price gained approximately 17.08% from an adjusted price of $165.34 on March 31, 2026, to $193.58 in premarket trading on July 22, 2026, following the Q2 earnings release.
2. The company demonstrated accelerated growth in its smoke-free product portfolio, which continues to be a primary revenue driver.
Philip Morris International's strategic shift towards reduced-risk products, including IQOS, VEEV, and ZYN, fueled significant growth. In fiscal Q1 2026, international smoke-free net revenues surged 24.7% (15.8% organically). This trend strengthened in fiscal Q2 2026, as smoke-free net revenues grew 14.2% (11.8% organically) and represented approximately 42% of total net revenues. Shipments of smoke-free products increased by 7.5% in Q2 2026, contributing to overall volume and market share gains in key international markets.
3. Philip Morris International exhibited robust profitability and enhanced cash flow generation during the period.
The strong top-line performance translated into significant improvements in profitability and cash flow. In fiscal Q2 2026, operating income increased 22.0% (10.7% organically). Furthermore, net cash provided by operating activities saw a substantial 61.0% year-on-year increase in fiscal Q2 2026, reaching $5.492 billion. This strong financial health and efficient cash generation likely bolstered investor confidence.
4. Management's reaffirmed full-year guidance, coupled with strategic investments, provided a positive outlook for sustained growth.
Despite the strong performance in the first half of 2026, management reiterated its full-year 2026 guidance. The company continues to target organic net revenue growth of 5% to 7% and currency-neutral adjusted diluted EPS growth of 7.5% to 9.5%, translating to an adjusted diluted EPS range of $8.26 to $8.41. This consistent outlook, even with planned increased investments in the U.S. for ZYN and the upcoming IQOS ILUMA launch, indicates confidence in the company's ability to deliver on its long-term objectives and maintain its growth trajectory.
Show less
Stock Movement Drivers
Fundamental Drivers
The 18.5% change in PM stock from 3/31/2026 to 7/22/2026 was primarily driven by a 21.3% change in the company's P/E Multiple.| (LTM values as of) | 3312026 | 7222026 | Change |
|---|---|---|---|
| Stock Price ($) | 163.98 | 194.30 | 18.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 40,648 | 41,493 | 2.1% |
| Net Income Margin (%) | 27.9% | 26.7% | -4.2% |
| P/E Multiple | 22.5 | 27.3 | 21.3% |
| Shares Outstanding (Mil) | 1,556 | 1,558 | -0.1% |
| Cumulative Contribution | 18.5% |
Market Drivers
3/31/2026 to 7/22/2026| Return | Correlation | |
|---|---|---|
| PM | 18.5% | |
| Market (SPY) | 14.9% | -15.7% |
| Sector (XLP) | 2.9% | 57.8% |
Fundamental Drivers
The 23.2% change in PM stock from 12/31/2025 to 7/22/2026 was primarily driven by a 24.0% change in the company's Net Income Margin (%).| (LTM values as of) | 12312025 | 7222026 | Change |
|---|---|---|---|
| Stock Price ($) | 157.67 | 194.30 | 23.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 39,992 | 41,493 | 3.8% |
| Net Income Margin (%) | 21.6% | 26.7% | 24.0% |
| P/E Multiple | 28.5 | 27.3 | -4.1% |
| Shares Outstanding (Mil) | 1,557 | 1,558 | -0.1% |
| Cumulative Contribution | 23.2% |
Market Drivers
12/31/2025 to 7/22/2026| Return | Correlation | |
|---|---|---|
| PM | 23.2% | |
| Market (SPY) | 9.9% | -1.1% |
| Sector (XLP) | 9.2% | 58.1% |
Fundamental Drivers
The 10.5% change in PM stock from 6/30/2025 to 7/22/2026 was primarily driven by a 35.1% change in the company's Net Income Margin (%).| (LTM values as of) | 6302025 | 7222026 | Change |
|---|---|---|---|
| Stock Price ($) | 175.76 | 194.30 | 10.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 38,386 | 41,493 | 8.1% |
| Net Income Margin (%) | 19.8% | 26.7% | 35.1% |
| P/E Multiple | 36.0 | 27.3 | -24.2% |
| Shares Outstanding (Mil) | 1,556 | 1,558 | -0.1% |
| Cumulative Contribution | 10.5% |
Market Drivers
6/30/2025 to 7/22/2026| Return | Correlation | |
|---|---|---|
| PM | 10.5% | |
| Market (SPY) | 22.0% | -6.9% |
| Sector (XLP) | 6.4% | 49.3% |
Fundamental Drivers
The 126.3% change in PM stock from 6/30/2023 to 7/22/2026 was primarily driven by a 78.4% change in the company's P/E Multiple.| (LTM values as of) | 6302023 | 7222026 | Change |
|---|---|---|---|
| Stock Price ($) | 85.85 | 194.30 | 126.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 32,035 | 41,493 | 29.5% |
| Net Income Margin (%) | 27.2% | 26.7% | -1.7% |
| P/E Multiple | 15.3 | 27.3 | 78.4% |
| Shares Outstanding (Mil) | 1,552 | 1,558 | -0.4% |
| Cumulative Contribution | 126.3% |
Market Drivers
6/30/2023 to 7/22/2026| Return | Correlation | |
|---|---|---|
| PM | 126.3% | |
| Market (SPY) | 74.6% | 8.1% |
| Sector (XLP) | 22.6% | 51.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| PM Return | 21% | 12% | -2% | 34% | 38% | 19% | 194% |
| Peers Return | 18% | -19% | -9% | 19% | 8% | -14% | -4% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 100% |
Monthly Win Rates [3] | |||||||
| PM Win Rate | 67% | 50% | 58% | 67% | 75% | 71% | |
| Peers Win Rate | 50% | 43% | 43% | 52% | 50% | 51% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 57% | |
Max Drawdowns [4] | |||||||
| PM Max Drawdown | -18% | -23% | -14% | -9% | -21% | -19% | |
| Peers Max Drawdown | -31% | -40% | -33% | -32% | -36% | -38% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: MO, TPB, UVV, XXII, PM. See PM Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/22/2026 (YTD)
How Low Can It Go
| Event | PM | S&P 500 |
|---|---|---|
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -12.0% | -6.7% |
| % Gain to Breakeven | 13.7% | 7.1% |
| Time to Breakeven | 328 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -30.5% | -33.7% |
| % Gain to Breakeven | 43.9% | 50.9% |
| Time to Breakeven | 261 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -19.2% | -19.2% |
| % Gain to Breakeven | 23.8% | 23.8% |
| Time to Breakeven | 52 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -12.2% | -3.7% |
| % Gain to Breakeven | 13.8% | 3.9% |
| Time to Breakeven | 80 days | 6 days |
| 2013 Taper Tantrum | ||
| % Loss | -18.7% | -0.2% |
| % Gain to Breakeven | 23.0% | 0.2% |
| Time to Breakeven | 275 days | 1 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -13.3% | -17.9% |
| % Gain to Breakeven | 15.4% | 21.8% |
| Time to Breakeven | 24 days | 123 days |
In The Past
Philip Morris International's stock fell 0.0% during the 2025 US Tariff Shock. Such a loss loss requires a 0.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | PM | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -30.5% | -33.7% |
| % Gain to Breakeven | 43.9% | 50.9% |
| Time to Breakeven | 261 days | 140 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -32.4% | -53.4% |
| % Gain to Breakeven | 47.9% | 114.4% |
| Time to Breakeven | 143 days | 1085 days |
In The Past
Philip Morris International's stock fell 0.0% during the 2025 US Tariff Shock. Such a loss loss requires a 0.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Philip Morris International (PM)
Philip Morris International (PM) is a leading global tobacco company that manufactures and sells a diverse portfolio of nicotine-containing products. While the company is historically known for traditional combustible cigarettes, it is strategically focused on developing and marketing smoke-free alternatives, aiming to replace cigarettes with scientifically substantiated, less harmful products.
The company's product offerings include a wide array of internationally recognized cigarette brands such as Marlboro, Parliament, Bond Street, Chesterfield, and L&M, along with various localized brands in specific markets. Crucially, PM is a pioneer in the smoke-free category, spearheaded by its IQOS platform. This platform features heated tobacco products under brands like HEETS, Fiit, and Miix, as well as nicotine-containing vapor products, all supported by their proprietary electronic devices and accessories.
Philip Morris International boasts an extensive global reach, distributing and marketing its products across numerous continents. Its primary markets span the European Union, Eastern Europe, the Middle East, Africa, South and Southeast Asia, East Asia, Australia, Latin America, and Canada, serving a vast international customer base with both its traditional and innovative smoke-free offerings.
AI Analysis | Feedback
The Coca-Cola of tobacco products.
The PepsiCo of nicotine products.
AI Analysis | Feedback
- Cigarettes: Philip Morris International manufactures and sells a wide range of traditional tobacco cigarettes globally.
- Smoke-free Products (IQOS): The company offers heated tobacco and nicotine-containing vapor products designed as potentially less harmful alternatives to traditional smoking.
- Related Electronic Devices and Accessories: These include the electronic devices and accompanying accessories necessary for using their smoke-free product lines.
- Other Nicotine-containing Products: Philip Morris International also provides various other products containing nicotine.
AI Analysis | Feedback
Philip Morris International (PM) primarily sells its products to individual consumers. Based on its product offerings and global market presence, the company serves the following categories of adult customers:
- Adult Smokers of Conventional Cigarettes: This category includes adult consumers who purchase and use traditional combustible cigarette brands such as Marlboro, Parliament, Bond Street, Chesterfield, and L&M.
- Adult Consumers of Heated Tobacco Products: This category comprises adult smokers who are transitioning to or exclusively using smoke-free heated tobacco products like IQOS, HEETS, Fiit, and Miix, seeking alternatives to conventional cigarettes.
- Adult Consumers of Other Nicotine-Containing Vapor Products: This category encompasses adult users of the company's nicotine-containing vapor products, which offer an alternative to traditional smoking.
AI Analysis | Feedback
AI Analysis | Feedback
Jacek Olczak, Group CEO PMI
Appointed Group CEO PMI in January 2026, Mr. Olczak previously served as PMI's Chief Executive Officer since May 2021. He began his career with PMI in 1993, holding finance and general management positions across Europe, including Managing Director of PMI's markets in Poland and Germany and President of the European Union Region. He was appointed Chief Financial Officer in 2012 and Chief Operating Officer in 2018. Before joining PMI, Mr. Olczak worked for BDO Binder. He holds a master's degree in economics from the University of Lodz, Poland. He is a key driver of PMI's transformation towards a smoke-free future, expanding the company's product portfolio into wellness and healthcare.
Emmanuel Babeau, Group Chief Financial Officer
Mr. Babeau was appointed Group Chief Financial Officer in January 2026, having served as PMI's Chief Financial Officer since May 2020. Prior to joining PMI, he spent over a decade at Schneider Electric, where he served as Deputy CEO in charge of Finance and Legal Affairs. He joined Schneider Electric in 2009 as Executive Vice President, Finance and a member of the Management Board. From 1993 to 2009, he worked at Pernod Ricard, initially as an Internal Auditor, and then in several executive positions, including Chief Financial Officer and Group Deputy Managing Director. He started his career at Arthur Andersen in 1990. Mr. Babeau sits on the board of Davide Campari-Milano N.V. and previously served as Vice Chairman of AVEVA Group plc and as an independent director at Sanofi S.A. and Sodexo.
Scott Coutts, Chief Global Operations Officer
Mr. Coutts was appointed Chief Global Operations Officer in January 2026, having served as PMI's Senior Vice President, Operations since January 2023. He oversees PMI's manufacturing footprint, supply chain, and related functions. Mr. Coutts joined PMI in 1995 as an Operations trainee at Philip Morris Australia. He held positions of increasing responsibility in various geographies, including Indonesia, Lithuania, and Russia. In 2016, he was appointed Vice President, Reduced-Risk Products Manufacturing and Supply Chain, and in 2018, Vice President, Global Manufacturing.
Moira Gilchrist, Chief Global Communications Officer
Dr. Gilchrist was appointed Chief Global Communications Officer in January 2026, having served as PMI's Chief Communications Officer since January 2024. Before that, she was Vice President, Strategic and Scientific Communications, a role she assumed in 2018. Since joining PMI in 2006, Dr. Gilchrist has held several positions, including leading the Reduced-Risk Products Corporate Affairs team, Director of Scientific Engagement within the R&D function, and working in both product development and commercialization. Prior to joining the company, Dr. Gilchrist worked in the pharmaceutical sector for more than a decade.
Stefano Volpetti, Chief Global Growth Officer
Mr. Volpetti became Chief Global Growth Officer in January 2026. He was previously President, Smoke-Free Products Category & Chief Consumer Officer since May 2025. He joined PMI in 2019 as Chief Consumer Officer. Before joining PMI, Mr. Volpetti worked at Procter & Gamble for 22 years and also served as Chief Marketing Officer at Luxottica Eyewear in 2015.
AI Analysis | Feedback
- Declining cigarette consumption volumes and increasing regulatory and taxation pressures on traditional tobacco products. The global trend towards reduced smoking due to health awareness campaigns, public smoking bans, and increased excise taxes consistently pressures the company's traditional cigarette business, which still forms a significant portion of its revenue.
- Regulatory scrutiny and potential restrictions on smoke-free products. While Philip Morris International is strategically investing in and expanding its portfolio of smoke-free products like IQOS, these products are not immune to evolving regulatory landscapes. Governments globally may impose stricter marketing limitations, flavor bans, or higher taxes as the long-term health impacts are further studied and debated, potentially hindering the growth and profitability of these next-generation products.
- Intense competition within the rapidly growing smoke-free and reduced-risk product categories. As the market for heated tobacco and e-vapor products expands, Philip Morris International faces increasing competition from other established tobacco companies and new entrants. This heightened competition could lead to pricing pressures, increased marketing and research & development expenses, and challenges in maintaining or gaining market share for its innovative products.
AI Analysis | Feedback
The expanding legalization and growing consumer adoption of cannabis and cannabis-derived products (e.g., vapes, edibles, beverages) present a clear emerging threat. As these products become more accessible and destigmatized in various global markets where Philip Morris International operates, they represent an alternative for adult consumers seeking relaxation, recreation, or stress relief. This trend could potentially divert discretionary spending and shift consumption habits away from nicotine products, impacting PM's core cigarette business and its strategic focus on smoke-free alternatives like IQOS.
AI Analysis | Feedback
Philip Morris International (PM) operates in several significant addressable markets for its main products and services, including traditional cigarettes, heated tobacco products, e-cigarettes and vaping products, and nicotine pouches.
Cigarettes
The global cigarette market was valued at approximately USD 1,143.4 billion in 2024 and is projected to reach USD 1,380.2 billion by 2033. The Asia-Pacific region holds the largest share of the global cigarette market, while the Middle East and Africa region is experiencing the fastest growth.
Heated Tobacco Products (Smoke-Free Products like IQOS)
The global heated tobacco products market, which includes products like IQOS, was estimated at USD 49.14 billion in 2024. This market is projected for substantial growth, with some estimates indicating it could reach USD 898.86 billion by 2030, growing at a compound annual growth rate (CAGR) of 63.2% from 2025 to 2030. The Asia Pacific region accounted for a dominant revenue share of 68.9% in the global market for heated tobacco products in 2024, with Japan being a major adopter.
E-cigarettes and Vaping Products (Nicotine-Containing Vapor Products)
The global e-cigarette and vape market size was estimated at USD 45.74 billion in 2025. Projections show this market could reach USD 462.14 billion by 2033, with a CAGR of 34.1% from 2026 to 2033. North America held a significant share of the market, accounting for 43.5% in 2025.
Nicotine Pouches
The global nicotine pouches market was estimated at USD 7.5 billion in 2024. This market is expected to grow to USD 44.2 billion by 2034, at a CAGR of 19.9%. North America dominated the nicotine pouches market with 78.9% of the revenue share in 2024.
AI Analysis | Feedback
Philip Morris International (PM) is set to drive future revenue growth over the next 2-3 years through several strategic initiatives, primarily focusing on its smoke-free product portfolio and leveraging its market position.
Here are 3-5 expected drivers of future revenue growth:
- Expansion and Innovation in Smoke-Free Products (IQOS, ZYN, VEEV): The company's most significant revenue growth driver is the continued global expansion and innovation within its smoke-free product categories. This includes heated tobacco units (HTUs) under the IQOS brand, which is seeing new variants like IQOS ILUMA and TEREA, and is the core driver of smoke-free growth. Additionally, nicotine pouches, particularly the ZYN brand acquired through Swedish Match, are experiencing rapid volume growth in key markets like the U.S. and Europe, fueled by expanded manufacturing capacity. The e-vapor product VEEV also contributes to this portfolio expansion.
- Strategic Geographic Market Expansion for Smoke-Free Portfolio: Philip Morris International is aggressively expanding the availability of its smoke-free products into new geographies and increasing penetration in existing markets. A notable upcoming driver is the re-entry of IQOS into the U.S. market in 2024-2025, following the termination of its licensing agreement with Altria, which is expected to accelerate growth. The company aims to make IQOS available in over 100 markets by mid-decade and its overall smoke-free portfolio reached 106 markets by Q4 2025.
- Sustained Pricing Power Across Product Categories: Philip Morris International consistently benefits from its ability to implement strategic price increases across both its smoke-free and traditional combustible tobacco products. This pricing power contributes significantly to organic net revenue growth, helping to offset the declining volumes of conventional cigarettes while enhancing profitability from the growing smoke-free segments.
AI Analysis | Feedback
Share Repurchases
- In June 2021, Philip Morris International authorized a new share repurchase program of up to $7 billion, with target spending of $5 billion to $7 billion over a three-year period.
- The company strategically paused share repurchases in 2025 to focus capital allocation on strategic investments and dividend growth.
- Philip Morris International made an "insignificant amount" of $209 million in share repurchases in 2022.
Share Issuance
- Philip Morris' shares outstanding showed slight increases from 1.552 billion in December 2022 to 1.558 billion in December 2025, representing minor annual increases between 0.06% and 0.19%.
Outbound Investments
- In 2021, Philip Morris International acquired Fertin Pharma for approximately $820 million and American inhaled drug specialist OtiTopic for an undisclosed sum. Additionally, it made an unconditional offer to acquire the U.K. pharmaceutical company Vectura for £1 billion.
- In March 2022, Philip Morris International acquired an 82.59% stake in Swedish Match for $16 billion, strengthening its position in alternative nicotine products, notably the Zyn nicotine pouch brand.
- PM Equity Partner, Philip Morris International's venture capital arm, invests in early-stage and growth-stage companies within life sciences, industrial technologies, consumer engagement, and product technologies.
Capital Expenditures
- Capital expenditures in 2025 were approximately $1.6 billion, primarily directed towards investments supporting the smoke-free business.
- For 2026, expected capital expenditures are projected to be between $1.4 billion and $1.6 billion, predominantly allocated to supporting the smoke-free business.
- From 2019 to 2023, Philip Morris International invested over €2.3 billion in research and development across Europe to drive innovation and scientific advancements.
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 72.17 |
| Mkt Cap | 1.5 |
| Rev LTM | 2,924 |
| Op Inc LTM | 211 |
| FCF LTM | 80 |
| FCF 3Y Avg | 68 |
| CFO LTM | 129 |
| CFO 3Y Avg | 127 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 0.7% |
| Rev Chg 3Y Avg | 4.5% |
| Rev Chg Q | 5.3% |
| QoQ Delta Rev Chg LTM | 1.2% |
| Op Inc Chg LTM | 0.5% |
| Op Inc Chg 3Y Avg | 6.4% |
| Op Mgn LTM | 17.6% |
| Op Mgn 3Y Avg | 22.4% |
| QoQ Delta Op Mgn LTM | -0.6% |
| CFO/Rev LTM | 4.4% |
| CFO/Rev 3Y Avg | 14.6% |
| FCF/Rev LTM | 2.7% |
| FCF/Rev 3Y Avg | 12.5% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.5 |
| P/S | 3.1 |
| P/Op Inc | 9.8 |
| P/EBIT | 10.3 |
| P/E | 27.2 |
| P/CFO | 13.6 |
| Total Yield | 6.6% |
| Dividend Yield | 2.9% |
| FCF Yield 3Y Avg | 4.4% |
| D/E | 0.2 |
| Net D/E | 0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 3.9% |
| 3M Rtn | 9.1% |
| 6M Rtn | 0.8% |
| 12M Rtn | 4.3% |
| 3Y Rtn | 98.9% |
| 1M Excs Rtn | 3.5% |
| 3M Excs Rtn | 5.0% |
| 6M Excs Rtn | -8.4% |
| 12M Excs Rtn | -14.8% |
| 3Y Excs Rtn | 34.1% |
Comparison Analyses
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Combustible tobacco products | 23,794 | 23,218 | 22,334 | 21,572 | 22,067 |
| Smoke-free | 16,854 | 14,660 | 12,840 | 10,190 | 9,338 |
| Total | 40,648 | 37,878 | 35,174 | 31,762 | 31,405 |
| $ Mil | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|
| European Union | 3,576 | 3,727 | 4,238 | 4,187 | 4,560 |
| Eastern Europe,Middle East and Africa | 3,425 | 4,121 | 3,779 | 3,726 | 3,229 |
| Latin America and Canada | 2,886 | 1,030 | 1,134 | 1,043 | 988 |
| Asia | 1,085 | 3,187 | 4,622 | 5,197 | 4,836 |
| Other | -349 | -363 | -258 | -307 | -281 |
| Total | 10,623 | 11,702 | 13,515 | 13,846 | 13,332 |
Price Behavior
| Market Price | $194.30 | |
| Market Cap ($ Bil) | 302.7 | |
| First Trading Date | 03/17/2008 | |
| Distance from 52W High | 0.0% | |
| 50 Days | 200 Days | |
| DMA Price | $181.88 | $166.17 |
| DMA Trend | up | up |
| Distance from DMA | 6.8% | 16.9% |
| 3M | 1YR | |
| Volatility | 32.7% | 27.8% |
| Downside Capture | -159.35 | -55.94 |
| Upside Capture | -40.75 | -20.54 |
| Correlation (SPY) | -20.4% | -6.9% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.63 | -0.53 | -0.23 | 0.07 | -0.11 | 0.14 |
| Up Beta | -0.16 | -0.62 | 0.31 | 0.31 | 0.41 | 0.19 |
| Down Beta | -1.02 | -0.44 | -0.56 | 0.14 | -0.16 | 0.21 |
| Up Capture | -47% | -10% | -7% | 8% | -13% | 6% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 12 | 25 | 36 | 71 | 137 | 422 |
| Down Capture | -78% | -106% | -101% | -26% | -53% | -18% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 9 | 16 | 27 | 54 | 114 | 325 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PM | |
|---|---|---|---|---|
| PM | 11.6% | 29.1% | 0.38 | - |
| Sector ETF (XLP) | 6.5% | 13.8% | 0.22 | 51.4% |
| Equity (SPY) | 20.0% | 12.6% | 1.16 | -7.1% |
| Gold (GLD) | 21.2% | 28.1% | 0.67 | 1.4% |
| Commodities (DBC) | 33.0% | 19.1% | 1.36 | 1.1% |
| Real Estate (VNQ) | 13.9% | 14.0% | 0.70 | 21.0% |
| Bitcoin (BTCUSD) | -43.6% | 42.9% | -1.21 | -2.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PM | |
|---|---|---|---|---|
| PM | 19.8% | 23.1% | 0.74 | - |
| Sector ETF (XLP) | 6.2% | 13.5% | 0.25 | 54.0% |
| Equity (SPY) | 12.8% | 17.1% | 0.58 | 21.1% |
| Gold (GLD) | 17.3% | 18.4% | 0.76 | 9.9% |
| Commodities (DBC) | 9.3% | 19.5% | 0.37 | 5.8% |
| Real Estate (VNQ) | 2.7% | 18.9% | 0.04 | 34.8% |
| Bitcoin (BTCUSD) | 15.2% | 53.5% | 0.46 | 4.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PM | |
|---|---|---|---|---|
| PM | 12.0% | 24.6% | 0.47 | - |
| Sector ETF (XLP) | 7.1% | 14.8% | 0.35 | 63.1% |
| Equity (SPY) | 15.1% | 17.9% | 0.72 | 40.6% |
| Gold (GLD) | 11.5% | 16.1% | 0.58 | 8.5% |
| Commodities (DBC) | 7.1% | 17.9% | 0.31 | 15.4% |
| Real Estate (VNQ) | 5.0% | 20.7% | 0.20 | 46.1% |
| Bitcoin (BTCUSD) | 58.5% | 66.2% | 0.99 | 8.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 7/22/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 4/22/2026 | 7.0% | 8.2% | 23.1% |
| 2/6/2026 | 0.4% | 3.8% | -4.8% |
| 10/21/2025 | -3.8% | -3.1% | -1.4% |
| 7/22/2025 | -8.4% | -12.6% | -6.5% |
| 4/23/2025 | 2.4% | 3.7% | 6.4% |
| 2/6/2025 | 10.9% | 14.4% | 15.2% |
| 10/22/2024 | 10.5% | 9.7% | 8.9% |
| 7/23/2024 | 2.2% | 6.7% | 11.0% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 14 | 14 | 14 |
| # Negative | 10 | 10 | 10 |
| Median Positive | 3.2% | 6.9% | 8.0% |
| Median Negative | -2.9% | -2.7% | -4.7% |
| Max Positive | 10.9% | 14.4% | 23.1% |
| Max Negative | -8.4% | -12.6% | -14.6% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 4/22/2026 | 7.0% | 8.2% | 23.1% |
| 2/6/2026 | 0.4% | 3.8% | -4.8% |
| 10/21/2025 | -3.8% | -3.1% | -1.4% |
| 7/22/2025 | -8.4% | -12.6% | -6.5% |
| 4/23/2025 | 2.4% | 3.7% | 6.4% |
| 2/6/2025 | 10.9% | 14.4% | 15.2% |
| 10/22/2024 | 10.5% | 9.7% | 8.9% |
| 7/23/2024 | 2.2% | 6.7% | 11.0% |
| 4/23/2024 | 3.8% | 1.6% | 6.6% |
| 2/8/2024 | -2.7% | -2.4% | 1.4% |
| 10/19/2023 | -2.7% | -3.4% | -2.1% |
| 7/20/2023 | -0.6% | -0.5% | -5.4% |
| 4/20/2023 | -4.7% | -3.3% | -8.8% |
| 2/9/2023 | 0.7% | -0.2% | -2.9% |
| 10/20/2022 | -1.7% | 3.6% | 10.0% |
| 7/21/2022 | 4.2% | 7.9% | 11.9% |
| 4/21/2022 | 2.0% | -1.3% | -2.5% |
| 2/10/2022 | 0.9% | 7.2% | -14.6% |
| 10/19/2021 | -1.7% | -0.9% | -4.5% |
| 7/20/2021 | -3.1% | 1.1% | 4.7% |
| 4/20/2021 | 2.5% | 3.0% | 6.6% |
| 2/4/2021 | 4.2% | 7.1% | 7.4% |
| 10/20/2020 | -5.8% | -5.4% | 0.7% |
| 7/21/2020 | 4.2% | 7.8% | 8.6% |
| SUMMARY STATS | |||
| # Positive | 14 | 14 | 14 |
| # Negative | 10 | 10 | 10 |
| Median Positive | 3.2% | 6.9% | 8.0% |
| Median Negative | -2.9% | -2.7% | -4.7% |
| Max Positive | 10.9% | 14.4% | 23.1% |
| Max Negative | -8.4% | -12.6% | -14.6% |
Recent Forward Guidance
Updated 7/8/2026Latest: Q1 2026 Earnings Reported 4/22/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q2 2026 Adjusted Diluted EPS | 2.02 | 2.04 | 2.07 | ||||
| 2026 Reported Diluted EPS | 7.56 | 7.63 | 7.71 | -3.9% | Lowered | Guidance: 7.95 for 2026 | |
| 2026 Adjusted Diluted EPS | 8.36 | 8.44 | 8.51 | -0.2% | Lowered | Guidance: 8.46 for 2026 | |
| 2026 Net Revenue Growth | 5.0% | 6.0% | 7.0% | 0.0% | Affirmed | Guidance: 6.0% for 2026 | |
| 2026 Organic Operating Income Growth | 7.0% | 8.0% | 9.0% | 0.0% | Affirmed | Guidance: 8.0% for 2026 | |
| 2026 Operating Cash Flow | 13.50 Bil | 0.0% | Affirmed | Guidance: 13.50 Bil for 2026 | |||
| 2026 Capital Expenditures | 1.40 Bil | 1.50 Bil | 1.60 Bil | 0.0% | Affirmed | Guidance: 1.50 Bil for 2026 | |
Prior: Q4 2025 Earnings Reported 2/6/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2026 Adjusted Diluted EPS | 1.8 | 1.82 | 1.85 | ||||
| 2026 Reported Diluted EPS | 7.87 | 7.95 | 8.02 | 6.8% | Higher New | Actual: 7.44 for 2025 | |
| 2026 Adjusted Diluted EPS | 8.38 | 8.46 | 8.53 | 12.6% | Higher New | Actual: 7.51 for 2025 | |
| 2026 Adjusted Diluted EPS, excluding currency | 8.11 | 8.19 | 8.26 | 10.5% | Higher New | Actual: 7.41 for 2025 | |
| 2026 Net Revenue Growth | 5.0% | 6.0% | 7.0% | -1.0% | Lower New | Actual: 7.0% for 2025 | |
| 2026 Organic Operating Income Growth | 7.0% | 8.0% | 9.0% | -2.8% | Lower New | Actual: 10.75% for 2025 | |
| 2026 Operating Cash Flow | 13.50 Bil | 17.4% | Higher New | Actual: 11.50 Bil for 2025 | |||
| 2026 Capital Expenditures | 1.40 Bil | 1.50 Bil | 1.60 Bil | -6.2% | Lower New | Actual: 1.60 Bil for 2025 | |
| 2028 Net Revenue Growth (CAGR) | 6.0% | 7.0% | 8.0% | ||||
| 2028 Operating Income Growth (CAGR) | 8.0% | 9.0% | 10.0% | ||||
| 2028 Adjusted Diluted EPS Growth (CAGR) | 9.0% | 10.0% | 11.0% | ||||
Q3 2025 Earnings Reported 10/21/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Reported Diluted EPS | 7.39 | 7.44 | 7.49 | 1.8% | Raised | Guidance: 7.3 for 2025 | |
| 2025 Adjusted Diluted EPS | 7.46 | 7.51 | 7.56 | 0.2% | Raised | Guidance: 7.5 for 2025 | |
| 2025 Adjusted Diluted EPS, excluding currency | 7.36 | 7.41 | 7.46 | ||||
| 2025 Smoke-free product volume growth | 12.0% | 13.0% | 14.0% | 0.0% | Affirmed | Guidance: 13.0% for 2025 | |
| 2025 Net revenue growth | 6.0% | 7.0% | 8.0% | 0.0% | Affirmed | Guidance: 7.0% for 2025 | |
| 2025 Organic operating income growth | 10.0% | 10.75% | 11.5% | -1.0% | Lowered | Guidance: 11.75% for 2025 | |
| 2025 Operating cash flow | 11.50 Bil | 0.0% | Affirmed | Guidance: 11.50 Bil for 2025 | |||
| 2025 Capital expenditures | 1.60 Bil | 0.0% | Affirmed | Guidance: 1.60 Bil for 2025 | |||
Insider Activity
Updated 5/8/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Dobrowolski, Reginaldo | Group Controller | Direct | Sell | 2202026 | 183.46 | 5,000 | 917,300 | 3,886,050 | Form |
| 2 | Dobrowolski, Reginaldo | Group Controller | Spouse | Sell | 2202026 | 183.58 | 1,000 | 183,580 | 1,331,689 | Form |
| 3 | Kennedy, Stacey | CEO PMI U.S. | Direct | Sell | 2202026 | 183.13 | 14,350 | 2,627,916 | 8,295,972 | Form |
| 4 | Babeau, Emmanuel | Group Chief Financial Officer | Direct | Sell | 2202026 | 181.61 | 33,800 | 6,138,418 | 29,868,125 | Form |
| 5 | Guerin, Yann | Group Chief Legal Officer | Direct | Sell | 2202026 | 181.69 | 4,000 | 726,760 | 6,252,316 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Dobrowolski, Reginaldo | Group Controller | Direct | Sell | 2202026 | 183.46 | 5,000 | 917,300 | 3,886,050 | Form |
| 2 | Dobrowolski, Reginaldo | Group Controller | Spouse | Sell | 2202026 | 183.58 | 1,000 | 183,580 | 1,331,689 | Form |
| 3 | Kennedy, Stacey | CEO PMI U.S. | Direct | Sell | 2202026 | 183.13 | 14,350 | 2,627,916 | 8,295,972 | Form |
| 4 | Babeau, Emmanuel | Group Chief Financial Officer | Direct | Sell | 2202026 | 181.61 | 33,800 | 6,138,418 | 29,868,125 | Form |
| 5 | Guerin, Yann | Group Chief Legal Officer | Direct | Sell | 2202026 | 181.69 | 4,000 | 726,760 | 6,252,316 | Form |
| 6 | Olczak, Jacek | Group CEO PMI | Direct | Sell | 2202026 | 182.18 | 80,000 | 14,574,400 | 115,200,430 | Form |
| 7 | De, Wilde Frederic | CEO PMI International | Direct | Sell | 2202026 | 182.58 | 20,000 | 3,651,600 | 24,376,804 | Form |
Investor Activity (13F)
Updated Jul 23, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Caledonia Investments PLC | $116.1 Mil | 13.6% | 15 | Hold | 13F |
| GQG Partners LLC | $8.3 Bil | 13.1% | 86 | TRIM -9.1% | 13F |
| Contrarius Group Holdings Ltd | $136.0 Mil | 7.7% | 47 | ADD +1532.6% | 13F |
| Gladstone Capital Management LLP | $66.8 Mil | 6.7% | 32 | Hold | 13F |
| Fundsmith LLP | $845.4 Mil | 6.6% | 34 | TRIM -16.5% | 13F |
| Fundsmith Investment Services LTD. | $277.4 Mil | 6.3% | 24 | TRIM -19.8% | 13F |
| Investment Management Associates Inc /Adv | $19.8 Mil | 5.4% | 27 | Hold | 13F |
| Independent Franchise Partners LLP | $423.4 Mil | 3.0% | 26 | TRIM -33.0% | 13F |
| Hamlin Capital Management, LLC | $121.0 Mil | 2.9% | 30 | Hold | 13F |
| Kinsale Capital Group, Inc. | $15.8 Mil | 2.5% | 41 | Hold | 13F |
| Keystone Financial Planning, Inc. | $5.8 Mil | 1.6% | 40 | TRIM -54.6% | 13F |
| Cincinnati Specialty Underwriters Insurance CO | $5.4 Mil | 1.3% | 46 | New | 13F |
| Brandywine Trust Co | $5.1 Mil | 0.9% | 31 | Hold | 13F |
| Troy Asset Management Ltd | $21.6 Mil | 0.6% | 30 | TRIM -6.6% | 13F |
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | As Of | Filing |
|---|---|---|---|---|---|---|
| Lone Pine Capital LLC | $424.0 Mil | 3.1% | 32 | Exited | Dec 31, 2025 | 13F |
| Atreides Management, LP | $65.1 Mil | 1.4% | 49 | Exited | Dec 31, 2025 | 13F |
| Hook Mill Capital Partners, LP | $15.7 Mil | 1.5% | 39 | Exited | Dec 31, 2025 | 13F |
| Keystone Financial Planning, Inc. | $5.8 Mil | 1.6% | 40 | TRIM -54.6% | Mar 31, 2026 | 13F |
| Independent Franchise Partners LLP | $423.4 Mil | 3.0% | 26 | TRIM -33.0% | Mar 31, 2026 | 13F |
| Fundsmith Investment Services LTD. | $277.4 Mil | 6.3% | 24 | TRIM -19.8% | Mar 31, 2026 | 13F |
| Fundsmith LLP | $845.4 Mil | 6.6% | 34 | TRIM -16.5% | Mar 31, 2026 | 13F |
| GQG Partners LLC | $8.3 Bil | 13.1% | 86 | TRIM -9.1% | Mar 31, 2026 | 13F |
| Troy Asset Management Ltd | $21.6 Mil | 0.6% | 30 | TRIM -6.6% | Mar 31, 2026 | 13F |
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| GQG Partners LLC | $8.3 Bil | 13.1% | 86 | TRIM -9.1% | 13F |
| Fundsmith LLP | $845.4 Mil | 6.6% | 34 | TRIM -16.5% | 13F |
| Independent Franchise Partners LLP | $423.4 Mil | 3.0% | 26 | TRIM -33.0% | 13F |
| Fundsmith Investment Services LTD. | $277.4 Mil | 6.3% | 24 | TRIM -19.8% | 13F |
| Contrarius Group Holdings Ltd | $136.0 Mil | 7.7% | 47 | ADD +1532.6% | 13F |
| Hamlin Capital Management, LLC | $121.0 Mil | 2.9% | 30 | Hold | 13F |
| Caledonia Investments PLC | $116.1 Mil | 13.6% | 15 | Hold | 13F |
| Gladstone Capital Management LLP | $66.8 Mil | 6.7% | 32 | Hold | 13F |
| Troy Asset Management Ltd | $21.6 Mil | 0.6% | 30 | TRIM -6.6% | 13F |
| Investment Management Associates Inc /Adv | $19.8 Mil | 5.4% | 27 | Hold | 13F |
| Kinsale Capital Group, Inc. | $15.8 Mil | 2.5% | 41 | Hold | 13F |
| Keystone Financial Planning, Inc. | $5.8 Mil | 1.6% | 40 | TRIM -54.6% | 13F |
| Cincinnati Specialty Underwriters Insurance CO | $5.4 Mil | 1.3% | 46 | New | 13F |
| Brandywine Trust Co | $5.1 Mil | 0.9% | 31 | Hold | 13F |
PM Trade Sentinel
High Conviction
CONVICTION RATIONALE
Conviction is high as Philip Morris International is successfully executing a margin-accretive pivot to smoke-free products, which comprised 41.5% of 2025 revenue. Strong pricing power in the legacy business, with a +8.5% combustible price variance in Q1 2026, funds this transition. The new growth engine is demonstrating robust momentum, with international smoke-free organic revenue up mid-teens in Q1.
STOCK ARCHETYPE
Branded Consumer Goods (Staples)Revenue = (Volume of Combustible Units * Price) + (Volume of Smoke-Free Units * Price) Mix shift from lower-margin combustible units to higher-margin smoke-free units, combined with pricing power across the entire portfolio.
INVESTMENT THESIS
Yes. The transition to higher-margin smoke-free products is driving profitable growth that more than offsets the managed decline of the legacy cigarette business.
- Smoke-free products generated 41.5% of total net revenues in 2025.
- Smoke-free product shipment volume grew 9.1% in Q1 2026.
- The company benefits from a higher margin on its smoke-free portfolio than on combustibles.
- Full-year 2026 guidance calls for organic operating income growth of +7% to +9%.
- Combustible pricing power remains strong, adding 8.5% in Q1 2026.
PRIMARY RISK
Global regulators could impose harsh taxes, flavor bans, or marketing restrictions on smoke-free products, treating them like cigarettes and stalling the company's primary growth engine.
- An EU-wide ban on characterizing flavors in heated tobacco products is in effect.
- Japan is harmonizing excise tax for heated tobacco products, with the next step on October 1, 2026.
- A U.S. class action trial regarding ZYN nicotine pouches is scheduled for December 7, 2026.
- Some governments have banned or are seeking to ban emerging nicotine products.
| KPI | Status | Rationale |
|---|---|---|
| Smoke-Free Product (SFP) Shipment Volume Growth | +9.1% year-over-year for Q1 2026 - Stable | The growth rate has decelerated from the high teens seen in mid-2025 but has stabilized and ticked up sequentially. Management noted the latest result is in line with the full-year target of high single-digit growth, suggesting this is a sustainable pace. |
| Combustible (Cigarette) Shipment Volume Growth | -5.1% year-over-year for Q1 2026 - Weakening | Management attributes the steeper decline to lapping an exceptionally strong prior-year comparison, when volumes grew +1.1%. The company forecasts a more moderate decline of around 3% for the full year, indicating the Q1 rate is not expected to persist. |
| Smoke-Free Products (SFP) Shipment Volume Growth | +12.8% (FY 2025 vs. FY 2024) | Measures the volume growth of the company's strategic growth engine, including heated tobacco units (HTUs), oral nicotine, and e-vapor. Strong growth indicates successful conversion of smokers and market expansion. |
| Heated Tobacco Units (HTU) Shipment Volume | 155,133 million units (FY 2025) | Represents the volume of the core IQOS consumable product, the largest component of the smoke-free business. It is a direct indicator of the scale and adoption of the company's flagship smoke-free platform. |
| Total International Market Share (Cigarette & HTU) | 29.2% (FY 2025) | Indicates the company's overall competitive position in its core international markets for both legacy and new product categories, excluding China and the U.S. |
SFP Momentum vs. Regulatory/Litigation Risk
BULL VIEW
The international smoke-free business is accelerating, with mid-teens organic revenue growth in Q1, providing enough financial momentum to absorb any impact from known regulatory changes.
CORE TENSION
Can accelerating smoke-free growth offset the financial impact of dated regulatory threats, which the market's recent +10.0% post-earnings reaction suggests it can?
PREVAILING SENTIMENT
The latest evidence favors the bull view. The +9.1% SFP volume growth in Q1 2026 demonstrates the underlying consumer demand remains strong despite a complex regulatory backdrop.
BEAR VIEW
Dated events, like the October 1 Japan tax hike and the December 7 ZYN trial, represent concrete, near-term threats that could materially damage the profitability of key growth products.
| Timeline | Event & Metric To Watch |
|---|---|
August 1, 2026 | New Group CFO Takes Role Watch: Succession of Group CFO Emmanuel Babeau by Massimo Andolina becomes effective. |
October 1, 2026 | Japan Tax Harmonization Impact Watch: Company commentary on volume, pricing elasticity, and market share for IQOS in Japan following the tax change. |
October 1, 2026 | Japan HTP Tax Harmonization Watch: Second step of excise tax harmonization for Heated Tobacco Products (HTPs) with cigarettes in Japan. |
10/21/2026 | Quarterly Performance and Guidance Watch: Any further revisions to full-year guidance, particularly for organic revenue, operating income, and EPS growth. |
10/29/2026 | US Market Read-Across Watch: Altria's commentary on nicotine pouch category growth, competitive intensity, and enforcement against illicit e-vapor products. |
December 7, 2026 | ZYN Class Action Trial Watch: Trial date set for the Kelly v. Philip Morris International putative class action regarding ZYN nicotine pouches. |
until March 31, 2027 | CFO Transition Period Ends Watch: Outgoing CFO Emmanuel Babeau will remain with the company as a Strategic Advisor to ensure a smooth transition. |
No set date | ZYN Litigation Developments Watch: Court ruling on the class certification motion in the Kelly v. Philip Morris International case. |
| Date | Event | Stock Impact |
|---|---|---|
2026-06-11 | Declared Next Quarterly Dividend Details: The Board of Directors declared a regular quarterly dividend of $1.47 per common share, payable on July 20, 2026. | +0.7% $181.45 -> $182.78 |
2026-05-20 | Announced CFO Succession Plan Details: Announced that Massimo Andolina will be appointed Group Chief Financial Officer, effective August 1, 2026, succeeding Emmanuel Babeau. | -1.6% $189.99 -> $186.91 |
2026-04-22 | Reported Q1 2026 Results Details: Performance exceeded expectations, but the company lowered its full-year 2026 guidance for Reported and Adjusted Diluted EPS. The stock reacted positively by 10.0% over two days. | +10.4% $151.99 -> $167.80 |
2026-03-05 | Declared Quarterly Dividend Details: The Board of Directors declared a regular quarterly dividend of $1.47 per common share. | -5.1% $176.00 -> $167.09 |
2026-02-06 | Reported Full-Year 2025 Results Details: The company reported 2025 results and renewed its three-year growth targets for 2026-2028. The two-day stock reaction around the earnings call was 0.0%. | -0.1% $178.91 -> $178.74 |
2026-01-23 | Presented ZYN MRTP Evidence Details: Company experts presented scientific evidence to the FDA's Tobacco Products Scientific Advisory Committee (TPSAC) for a Modified Risk Tobacco Product (MRTP) designation for ZYN nicotine pouches. | +3.4% $167.16 -> $172.77 |
Position Sizing
2% - 4%
REDUCED POSITION
Sizing is volatility-based: PM trades at roughly 29% annualized options-implied volatility versus about 15% for the S&P 500 (2.0x the market), around the 89th percentile of its own trailing year. A 2% - 4% position keeps a single-name swing of that size within a diversified portfolio's risk budget.
Diversification Alternatives
MO - Altria Group, Inc.
U.S. Market FocusAltria offers pure-play exposure to the U.S. nicotine market and operates with a higher gross margin of 72.6% compared to PM's 67.3%.
TPB - Turning Point Brands
High-Growth Niche PlayAs a smaller competitor, TPB offers much higher growth potential in the Modern Oral segment, which saw net sales increase 133% year-over-year in its latest quarter.
PMI is a consumer staples giant executing a self-disruption, leveraging cash flows from its declining but highly profitable cigarette business to fund a rapid, margin-accretive pivot to dominate the future of nicotine with smoke-free products.
The company is actively managing the decline of its legacy combustible cigarette business, using strong pricing power to generate cash. This cash is aggressively reinvested into building a dominant, multi-category portfolio of smoke-free products (IQOS, ZYN, VEEV). The core thesis is that this transition will replace declining cigarette volumes with higher-margin, growing smoke-free volumes, leading to sustained top and bottom-line growth.
Faster-than-expected adoption of IQOS and ZYN in key markets, favorable regulatory decisions (like FDA authorizations) that differentiate smoke-free from cigarettes, and continued strong pricing power in combustibles.
Draconian government regulations that treat smoke-free products the same as cigarettes (e.g., flavor bans, high excise taxes), a significant slowdown in smoke-free volume growth, or an accelerated decline in combustible profits that crimps investment capacity.
Short-term quarterly shipment volatility due to inventory movements or timing of price increases; minor market share fluctuations in the combustible segment.
Repricing Catalyst
Successful execution of the U.S. strategy, including scaling ZYN innovations and achieving a full commercial launch of IQOS ILUMA, which would open up the world's largest smoke-free market.
International Smoke-Free
$16.9B TTM (41% of Total)What It Is
Sells smoke-free products, including IQOS heat-not-burn devices and consumables (HTUs), ZYN nicotine pouches, and VEEV e-vapor products, to distributors, wholesalers, retailers, and directly to consumers via e-commerce and brand retail stores in markets outside the United States.
Who Pays & How
Distributors, retailers, and consumers pay for innovative, reduced-risk alternatives to smoking. Consumers are drawn to the product experience, brand strength (particularly IQOS), and the perceived health benefits of switching from combustible cigarettes.
Competition
Philip Morris International — Investor Video Playlist
Industry Resources
| Consumer Staples Resources |
| FoodNavigator |
| Consumer Goods Technology (CGT) |
| Beverage Digest |
| Tobacco Resources |
| Tobacco Reporter |
| Tobacco Journal International |
| CSP Daily News - Tobacco |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.